Moustafa M. Abdelaziz

Moustafa M. Abdelaziz

Auto-generated profile, based on publicly available information

Moustafa M. Abdelaziz

Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in ACS Omega
Verified
Journal Article
Open access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
AHAmr Hefnawy
Amr Hefnawy
Assem Antar AbdelalimAssem Antar Abdelalim
Assem Antar Abdelalim
MAMenna M Abdellatif
Menna M Abdellatif
MKMahmoud A. F. Khalil
Mahmoud A. F. Khalil
IKIslam A Khalil
Islam A Khalil
Drug resistance is a global health challenge with thousands of deaths annually caused by bacterial multidrug resistance (MDR). Efforts to develop new antibacterial molecules do not meet the mounting needs imposed by the evolution of MDR. An alternative approach to overcome this challenge is developing targeted formulations that can enhance the therapeutic efficiency and limit side effects. In this aspect, vancomycin is a potent antibacterial agent that has inherent bacterial targeting properties by binding to the D-Ala-D-Ala moiety of the bacterial peptidoglycan. However, the use of vancomycin is associated with serious side effects that limit its clinical use. Herein, we report the development of vancomycin-conjugated magnetic nanoparticles using a simple conjugation method for targeted antibacterial activity. The nanoparticles were synthesized using a multistep process that starts by coating the nanoparticles with a silica layer, followed by binding an amide linker and then binding the vancomycin glycopeptide. The developed vancomycin-conjugated magnetic nanoparticles were observed to exhibit a spherical morphology and a particle size of 16.3 ± 2.6 nm, with a silica coating thickness of 5 nm and a total coating thickness of 8 nm. The vancomycin conjugation efficiency on the nanoparticles was measured spectrophotometrically to be 25.1%. Additionally, the developed formulation retained the magnetic activity of the nanoparticles, where it showed a saturation magnetization value of 51 emu/g, compared to 60 emu/g for bare magnetic nanoparticles. The in vitro cell biocompatibility demonstrated improved safety where vancomycin-conjugated nanoparticles showed IC50 of 183.43 μg/mL, compared to a much lower value of 54.11 μg/mL for free vancomycin. While the antibacterial studies showed a comparable activity of the developed formulation, the minimum inhibitory concentration was 25 μg/mL, compared to 20 μg/mL for free vancomycin. Accordingly, the reported formulation can be used as a platform for the targeted and efficient delivery of other drugs.

15 August 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Amr HefnawyAmr Hefnawy
Amr Hefnawy
AAAhmed S. Abdelhamid
Ahmed S. Abdelhamid
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
AEAhmed O. Elzoghby
Ahmed O. Elzoghby
IKIslam A Khalil
Islam A Khalil

1 November 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HGHuan Gong
Huan Gong
JGJ. Daniel Griffin
J. Daniel Griffin
CGChad E. Groer
Chad E. Groer
SWSa Wu
Sa Wu
GDGrant M. Downes
Grant M. Downes
CBCory Berkland
Cory Berkland

3 January 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
Amr HefnawyAmr Hefnawy
Amr Hefnawy
Assem Antar AbdelalimAssem Antar Abdelalim
Assem Antar Abdelalim
MAMenna M Abdellatif
Menna M Abdellatif
MKMahmoud A.F. Khalil
Mahmoud A.F. Khalil
IKIslam A Khalil
Islam A Khalil

17 February 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
YZYilue Zhang
Yilue Zhang
MBMaribel Espinoza Ballesteros
Maribel Espinoza Ballesteros
CGChad Groer
Chad Groer
DRDavid S. Richards
David S. Richards
MFM. Laird Forrest
M. Laird Forrest
Evaluation of pharmacokinetics is a cornerstone in the developability assessment of therapeutic monoclonal antibodies (mAbs). For accurate evaluation of mAbs' concentration-time profile, administered mAbs should be isolated from the interfering host proteins in serum samples. While there are multiple approaches to purify and quantify the administered mAb, they are limited by drawbacks such as low specificity, relatively-large plasma volume requirements, and tedious procedures for sample preparation and analysis. Here, we present an immunoprecipitation assay that uses a highly specific anti-human IgG1 antibody coupled with magnetic beads (R10-coupled Dynabeads) for the purification of adalimumab and forced-oxidized variants. The specificity and binding capacity of R10-coupled Dynabeads were confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. To demonstrate the wide applicability of this method, two different stressed variants involving mixtures with rat proteins were examined which are chemical oxidation stress and physical agitation stress. The results showed comparable recovery of native adalimumab and oxidized variants from in vitro and in vivo rat proteins mixture. R10-coupled Dynabeads also recovered aggregated species, but the method itself induced more aggregate formation as evident from analysis by dynamic light scattering and background membrane imaging. Pharmacokinetic evaluation showed a typical concentration-time profile for native adalimumab which is broadly consistent with reported profiles. This method can provide an efficient and highly-specific recovery of human IgG1 and degradation products from preclinical biological samples, provided that the epitope recognized by the used anti-human IgG antibody is retained and accessible. Furthermore, the integration of R10-coupled Dynabeads purification, Trypsin/Lys-C digestion, and QToF LC-MS/MS analysis enabled efficient capture of the oxidized species generated by AAPH and H2O2 (% sequence coverage ≥ 90%). Accordingly, this combined workflow can be applied to study in vivo modifications of therapeutic proteins (e.g. oxidation, deamidation) after exposure to an anatomical environment.

17 October 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
CGChad Groer
Chad Groer
YZYilue Zhang
Yilue Zhang
DRDavid S. Richards
David S. Richards
MBMaribel Espinoza Ballesteros
Maribel Espinoza Ballesteros
MFM. Laird Forrest
M. Laird Forrest